Risky sexual practices among youth attending a sexually transmitted infection clinic in Dar es Salaam, Tanzania by Mhalu F, Chalamilla G, Moshiro C, Urassa W, Sandstrom E

Get full text

Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam by Ngatoluwa M, Munseri P, Janabi M, Mhalu F, Sandstrom E, Bakari M

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans? by Albert J, Sandström E, Gudmundsdotter L, Aperia K, Engström G, Wahren B, Bråve A

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees by Biberfeld G, Sandström E, Gaines H, Marovich M, Wahren B, Karlén K, Aboud S, Nilsson C, Godoy-Ramirez K

High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania by Mann PJ, Munseri P, Kaluwa B, Missanga M, Lwakatare J, Hoelscher M, Bakari M, Janabi M, Maboko L, Sandström E, Kroidl A

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults by Joachim A, Nilsson C, Aboud S, Lyamuya EF, Robb M, Marovich M, Ochsenbauer C, Wahren B, Sandström E, Biberfeld G, Ferrari G, Polonis VR

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA by Wahren B, Moss B, Earl P, Michael N, Marovich M, Robb M, Brave A, Hejdeman B, Stout R, Mwanyika L, Mbwana J, Janabi M, Lyamuya E, Aris EA, Moshiro C, Buma D, Francis J, Nilsson C, Aboud S, Bakari M, Biberfeld G, Pallangyo K, Mhalu F, Sandstrom E

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime by Bauer A, Podola L, Haule A, Sudi L, Nilsson C, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, Joseph S, McCormack S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Kroidl A, Geldmacher C

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen by Podola L, Bauer A, Haule A, Sudi L, Nilsson C, Godoy-Ramirez K, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, McCormack S, Joseph S, Lyamuya E, Hoelscher M, Wahren B, Sandström E, Biberfeld G, Geldmacher C, Kroidl A

Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee. by Aboulker, J, Babiker, A, Clumeck, N, Cooper, D, Darbyshire, J, Dormont, J, Gatell, J, Goebel, F, Laurian, Y, Mannucci, P, Mathiesen, L, Peto, T, Reiss, P, Sandstrom, E, Savidge, G, Seligmann, M, Smith, D, Stingl, G, Veenstra, J, Weller, I, Yeo, J, Lafon, E, McCormack, S, Swart, A, Withnall, R

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine by Munseri P, Kroidl A, Nilsson C, Moshiro C, Aboud S, Joachim A, Geldmacher C, Aris E, Buma D, Lyamuya E, Gotch F, Godoy-Ramirez K, Pallangyo K, Maboko L, Marovich M, Robb M, Hoelscher M, Janabi M, Mann P, Joseph S, Mfinanga S, Stoehr W, Mhalu F, Wahren B, Biberfeld G, McCormack S, Sandstrom E, Bakari M